Navigation Links
K-V Pharmaceutical Company Engages BDO USA, LLP as Independent Registered Accountants
Date:8/3/2010

York Stock Exchange, including with respect to minimum share price and public float, could result in delisting of our shares on the New York Stock Exchange, which would harm the market price of the Company's Class A common stock and Class B common stock;
  • the risk that even if the price and 30-day average price of the Company's Class A common stock and Class B common stock closes at $1.00 and above on any given day or for any given 30-day period, the Company can provide no assurance that they will remain at such levels thereafter;
  • the risk that BDO will be unable to complete the audit of the Company's financial statements to be included in its annual report for its fiscal year ended March 31, 2010 on a timely basis which would impact the Company's compliance with New York Stock Exchange listing standards, and the Securities Exchange Act of 1934, as amended;
  • the risk that BDO will be unable to complete on a timely basis the review of the Company's financial statements to be included in its fiscal 2011 Form 10-Q's; and
  • the risks detailed from time-to-time in the Company's filings with the SEC.

  • This discussion is not exhaustive, but is designed to highlight important factors that may impact the Company's forward-looking statements.

    Because the factors referred to above, as well as the statements included elsewhere in this press release, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by the company or on the Company's behalf, you should not place undue reliance on any forward-looking statements.  All forward-looking statements attributable to the Company are expressly qualified in their entirety by the cautionary statements in this "Cautionary Note Regarding Forward-Looking Statements" and the risk factors that are included un
    '/>"/>

    SOURCE K-V Pharmaceutical Company
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. CORRECTED: Ampio Pharmaceuticals Announces Completion of Negotiations for Acquisition of DMI BioSciences, Inc.
    2. Vanda Pharmaceuticals to Announce Second Quarter 2010 Financial Results on August 5, 2010
    3. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010
    4. Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients
    5. China BCT Further Expands its Footprint by Opening 12 New Retail Pharmaceutical Stores
    6. Amira Pharmaceuticals Hits Two Development Milestones Related to FLAP Inhibitor Program
    7. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
    8. Viscira Delivers Key Presentation to Pharmaceutical Marketing Professionals at Leading Digital Industry Conference
    9. Biostar Pharmaceuticals, Inc. Appoints New Chief Financial Officer
    10. United Therapeutics and Lees Pharmaceutical Sign Remodulin Distribution Agreement for China
    11. Angiotech Pharmaceuticals Announces Conference Call and Webcast
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/11/2014)... 11, 2014 Research and Markets  has ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... http://photos.prnewswire.com/prnh/20130307/600769 ... (either DNA or RNA) into cells. This technology helps ... cells and protein metabolism by affecting the nuclear genes. ...
    (Date:7/11/2014)... , July 11, 2014 /CNW/ - Sunovion Pharmaceuticals ... APTIOM TM (eslicarbazepine acetate) for use as a ... in patients with epilepsy who are not satisfactorily controlled ... for use in patients under 18 years of age. ... common neurological disorders and according to Epilepsy Canada, it ...
    (Date:7/10/2014)... July 10, 2014 Women in ... access to an additional family planning option. Sayana® ... contraception at all levels of the health system ... of a widely used contraceptive—Pfizer’s Depo-Provera® (depot medroxyprogesterone ... Faso is the first of four African countries ...
    (Date:7/10/2014)... Cleveland, Ohio (PRWEB) July 10, 2014 ... in ion channel-expressing cell lines, and the gap that ... new cells that expand its industry-leading portfolio of validated ... focuses on ion channel-expressing cell lines, as ion channels ... able to control this activity creates the potential to ...
    Breaking Biology Technology:International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3
    ... Corporation is,pleased to announce it has obtained US FDA ... C-QUR Edge(TM) V-Patch and C-QUR Lite(TM),V-Patch., These new ... and,reinforcement of soft tissue, including hernia repair -- a ... each year. This novel,technology combines Atrium,s ProLite Ultra(TM) polypropylene ...
    ... ENMD-2076, ROCKVILLE, Md., May 8 ... developing therapeutics for,the treatment of cancer and ... has joined the University of Colorado Cancer,Center ... ENMD-2076 in advanced cancer,patients. Dr. Geoffrey Shapiro, ...
    ... May 7, 2008 / b3c newswire / – ... entered into a joint agreement to supply customers ... complex structures. , Under the agreement, CRELUX and ... crystal-grade protein kinase portfolio, optimized and quality-controlled for ...
    Cached Biology Technology:Atrium Medical Receives FDA Approval for its Novel C-QUR Lite(TM) V-Patch and C-QUR Edge(TM) V-Patch 2Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor 2Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor 3CRELUX and ProQinase establish joint crystal-grade kinase protein and structures platform 2CRELUX and ProQinase establish joint crystal-grade kinase protein and structures platform 3
    (Date:7/11/2014)... has demonstrated that transplantation of mesenchymal stem cells can ... mouse models of Alzheimer,s disease (AD) and improve tissue ... Few studies are reported on the therapeutic effect of ... and on the effect on oxidative injury and neurogenesis ... and her team, School of Life Sciences, Tsinghua University, ...
    (Date:7/11/2014)... study the proteins that let nerve cells send out ... upon a biological tactic that may offer a new ... safe and environmentally responsible way. , Their findingthat ... species and harmless for a closely related onesuggests that ... harming beneficial species like bees. A summary of the ...
    (Date:7/10/2014)... 30, 2014  Aware, Inc. (NASDAQ: AWRE ... previously announced on June 26, 2014 that its Board ... $1.75 per share, or approximately $40 million in total.  ... 2014 and a payment date of July 24, 2014.  ... had set an ex-dividend date for this special cash ...
    Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2
    ... Everyone wants to live in the nicest possible house, ... at Tufts University,s School of Arts and Sciences and ... locate new and improved housing using previously unknown social ... experiments and computer models to uncover some surprising new ...
    ... Here,s another reason to kick the soda habit. New ... ( http://www.fasebj.org ) shows that high levels of phosphates ... than once thought. That,s because researchers found that the ... phosphate levels may also increase the prevalence and severity ...
    ... 23, 2010) Moffitt Cancer Center announces steadily growing ... for selecting chemotherapy for Non Small Lung Cancer patients. ... with lung cancer. The ERCC1 Analysis measures ERCC1 ... The correlation between ERCC1 levels and therapy ...
    Cached Biology News:Social networking helps hermit crabs find homes 2Social networking helps hermit crabs find homes 3Phosphorous in sodas and processed foods accelerates signs of aging say Harvard scientists 2Moffitt Cancer Center: Growing interest in prognostic test for non-small cell lung cancer 2
    ... are complete ready-to-use reagents for the isolation ... specifically formulated for the isolation of genomic ... specifically formulated for the isolation of genomic ... DNAzol Reagents can be used for restriction ...
    Apoptosis Detection Systems and Reagents...
    Bovine Serum Available Anticoagulants: N-02: Citrate N-04: Heparin (Na) N-06: K2EDTA N-08: Potassium Oxalate N-10: EDTA (Na) N-03: Alsevers N-05: ACD N-07: CPD N-09: K3EDTA N-11:...
    Anti-Mouse Qa.m8, Ascites (Clone 5035-24.1) (mouse IgG3)...
    Biology Products: